Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | POLB | P06746 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | ERN1 | O75460 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | ALPG | P10696 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22840696 | 0.90 | KDM4E (0.46) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL2570250 | 0.85 | HPGD (0.43) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL2555270 | 0.84 | CYP2D6 (0.51) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL30406437 | 0.84 | CYP2D6 (0.51) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL14930229 | 0.80 | KDM4E (0.67) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL2553024 | 0.79 | ERN1 (0.58) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL22840642 | 0.79 | CYP2D6 (0.43) | MEN1KMT2APOLB | |
| SCHEMBL2547939 | 0.79 | CSNK2A1 (0.54) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL2568190 | 0.77 | ERN1 (0.56) | MEN1KMT2APOLBKDM4EALDH1A1 | |
| SCHEMBL23188368 | 0.73 | RAB9A (0.37) | MEN1KMT2AKDM4EALDH1A1ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110172051-B | IRE-1 alpha inhibitors | 复星弘创(苏州)医药科技有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| US-11337956-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3799870-A1 | IRE-1A INHIBITORS | Fosun Orinove Pharmatech, Inc. (CN) | 2021-04-07 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| EP-3409276-B1 | IRE-1A INHIBITORS | FOSUN ORINOVE PHARMATECH INC (CN) | 2020-12-30 | — | — | EP | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-10-17 | — | — | US | disclosed |
| US-10357475-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2019-07-23 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-9040714-B2 | IRE-1α inhibitors | MANNKIND CORPORATION (US) | 2015-05-26 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20150141424-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2015-05-21 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | MANNKIND CORPORATION (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2555768-A2 | IRE-1 INHIBITORS | MannKind Corporation (US) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011127070-A2 | IRE-1α INHIBITORS | MANNKIND CORPORATION (US) | 2011-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150141424-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | MEN1 3936/4885KMT2A 4481/4885POLB 2417/4885 |
| US-11337956-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | MEN1 3922/4885KMT2A 4345/4885POLB 2606/4885 |
| US-20190314330-A1 | IRE-1ALPHA INHIBITORS | ERN1, XBP1, ERN2 | MEN1 3936/4885KMT2A 4481/4885POLB 2417/4885 |
| US-10357475-B2 | IRE-1α inhibitors | XBP1, ERN1, ERN2 | MEN1 3922/4885KMT2A 4345/4885POLB 2606/4885 |
| US-20130116247-A1 | IRE-1alpha INHIBITORS | ERN1, XBP1, ERN2 | MEN1 3674/4885KMT2A 4509/4885POLB 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.